Moderna Stock Surges 72% in Q1 Amid FDA Leadership Shifts and New Vaccine Review

Moderna (MRNA) shares recorded a massive 72% rally during the first quarter of 2026, marking its position as the sixth-best performer in the S&P 500 index. This significant growth is largely attributed to the resolution of key legal challenges and favorable shifts within the U.S. Food and Drug Administration (FDA). Investors reacted positively to the impending departure of a high-ranking FDA official known for skepticism toward vaccines, which is expected to ease regulatory hurdles. Furthermore, the FDA is currently reviewing Moderna's latest flu vaccine candidate, providing a clear path for future revenue growth. The combination of settling major lawsuits and a more supportive regulatory environment has created a strong bullish momentum for the biotech firm. These developments significantly strengthen Moderna's fundamental outlook for the remainder of the year.